Press Releases 2014
Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging - Oct 16, 2014
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads...
Boston Scientific announces new developments in its Electrophysiology portfolio - Oct 02, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias...
Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial - Aug 30, 2014
Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure.
Boston Scientific at Cardiostim 2014 - Jul 11, 2014
A short video summary of Cardiostim 2014, featuring interviews with Dr Maria Grazia Bongiorni, Dr Michele Gulizia and Prof. Andreas Bollmann on the S-ICD™ System and the..
Boston Scientific welcomes new guidance on the use of cardiac technologies for patients with arrhythmia or heart failure - Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac...
New Data Illustrate Long-Term Safety And Effectiveness Of The Boston Scientific S-ICD™ System - Apr 01, 2014
Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week in the European Heart Journal.
New Long-term Data Demonstrate Patients with Mild Heart Failure Sustained Lower Mortality Rates After Receiving Boston Scientific CRT Defibrillators - Mar 30, 2014
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX) exclusively sponsored and...
Boston Scientific Announces CE Mark Approval and First Implants of Ingevity™ MRI Pacing Leads - Mar 14, 2014
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads.